Disc Medicine, Inc. - Common Stock (IRON)

Disc Medicine reported a wider Q3 2025 loss but advanced its bitopertin NDA with FDA priority review, targeting a 2025/2026 launch.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months.

The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions.

Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

As of mid-October 2025, a compelling and diverse group of companies, spanning utilities, biotechnology, advanced materials, and defense, have seen their stocks reach impressive 52-week highs. This significant market event underscores a nuanced financial landscape where both defensive stability and high-growth innovation are being richly rewarded. The surge in valuations

IRON stock results show that Disc Medicine beat analyst estimates for earnings per share the second quarter of 2024.

IRON stock results show that Disc Medicine missed analyst estimates for earnings per share the first quarter of 2024.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.